Abstract:Abstract Background Insulin Resistance (IR) predisposes to cardiometabolic disorders, which are common in schizophrenia and are associated with excess morbidity and mortality. The mechanisms of association remain unknown. We aimed 1) To use genetic data to examine the direction of association between IR and related cardiometabolic risk factors, and schizophrenia; 2) To examine whether inflammation could be a shared mechanism for IR and schizophrenia. Methods We used two-sample uni-variable Mendelian randomization (MR) to examine whether genetically-predicted IR-related cardiometabolic risk factors (Fasting insulin (FI), high-density lipoprotein (HDL), triglycerides (TG), low-density lipoprotein, fasting plasma glucose, glycated haemoglobin, leptin, body mass index, glucose tolerance and type 2 diabetes) may be causally associated with schizophrenia. We used the most recent summary statistics for genetic variants associated with schizophrenia and IR-related cardiometabolic risk factors from publicly-available large genome-wide association studies (GWAS). We used bi-directional MR to examine direction of association. To examine whether inflammation could be a shared mechanism for IR and schizophrenia, we first conducted a sensitivity analysis by performing MR using only cardiometabolic genetic variants that were also associated with inflammation, at genome-wide significance. Second, we used multi-variable MR (MVMR) to examine associations between cardiometabolic risk factors and schizophrenia after adjusting for genetically-predicted levels of C-reactive protein. Results In analyses using all associated genetic variants, genetically predicted levels of leptin were associated with risk of schizophrenia (OR=2.54 per SD increase in leptin; 95% CI, 1.02–6.31). In analyses using inflammation-related variants, genetically predicted levels of FI (OR=2.76 per SD increase in FI; 95% C.I., 1.31–6.17), TG (OR=2.90 per SD increase in TG; 95% C.I., 1.36–6.17), and HDL (OR=0.56 per SD increase in HDL; 95% C.I., 0.37–0.83) were associated with schizophrenia. The associations completely attenuated in MVMR analyses controlling for CRP. There was no evidence of an association between genetically-predicted schizophrenia liability and cardiometabolic factors. Discussion The IR phenotype of FI, TG and HDL could be associated with schizophrenia over and above common sociodemographic and lifestyle factors. This association is likely explained by a common inflammatory mechanism. Interventional studies are required to test whether inflammation could represent a putative therapeutic target for the treatment and prevention of cardiometabolic disorders in schizophrenia.

Schizophrenia and cardiometabolic abnormalities: A Mendelian randomization study

Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies.

Exploring the Relationship Between Schizophrenia and Cardiovascular Disease: A Genetic Correlation and Multivariable Mendelian Randomization Study

M88. EVIDENCE FOR INFLAMMATION AS A PUTATIVE SHARED MECHANISM FOR INSULIN RESISTANCE AND SCHIZOPHRENIA

Cigarette Smoking and Schizophrenia: Mendelian Randomisation Study.

Exploring shared genetic bases and causal relationships of schizophrenia and bipolar disorder with 28 cardiovascular and metabolic traits

Characterizing the Causal Associations Between Blood Metabolites, Schizophrenia and Neurocognitive Traits Using a Mendelian Randomization Study

Evidence for Shared Genetic Aetiology Between Schizophrenia, Cardiometabolic, and Inflammation-Related Traits: Genetic Correlation and Colocalization Analyses

Metabolic Disorders and Risk of Cardiovascular Diseases: a Two-Sample Mendelian Randomization Study

Exploring Lead loci shared between schizophrenia and Cardiometabolic traits

Body mass index, smoking behavior, and depression mediated the effects of schizophrenia on chronic obstructive pulmonary disease: trans-ethnic Mendelian-randomization analysis

Cardiometabolic biomarkers and comorbid metabolic syndrome in schizophrenia: A cross-sectional study of long-term clozapine/olanzapine users

Genetic predisposition and antipsychotic treatment effect on metabolic syndrome in schizophrenia: a ten-year follow-up study using the Estonian Biobank

Associations of schizophrenia with arrhythmic disorders and electrocardiogram traits: genetic exploration of population samples

Schizophrenia and Types of Stroke: A Mendelian Randomization Study

Major Depressive Disorder and Cardiometabolic Diseases: a Bidirectional Mendelian Randomisation Study

Genetic evidence for the causal relations between metabolic syndrome and psychiatric disorders: a Mendelian randomization study

Gut microbiome and schizophrenia: insights from two-sample Mendelian randomization

Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia

Circulating inflammatory cytokines influencing schizophrenia: a Mendelian randomization study

Evaluating the causal relationship of Levo-carnitine and risk of schizophrenia: a bidirectional two-sample mendelian randomization study